Recent treatments of interstitial lung disease with systemic sclerosis

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 9, Issue , 2016, Pages 97-110

  Yasuoka, Hidekata ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interstitial lung disease; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

ABATACEPT; ANIFROLUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOPHOSPHAMIDE; FRESOLIMUMAB; GLUCOCORTICOID; IMATINIB; IMMUNOGLOBULIN; INTERFERON RECEPTOR; METELIMUMAB; MYCOPHENOLATE MOFETIL; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BRONCHOSCOPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROESOPHAGEAL REFLUX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MYOPATHY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; POLYARTHRITIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCORING SYSTEM; SYSTEMIC SCLEROSIS; THERAPY EFFECT;

EID: 84960345465     PISSN: None     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S23315     Document Type: Article

References (131)

1. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176:755-9.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-4.
3. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and man-agement. Am J Respir Crit Care Med. 2011;183:788-824.
4. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34:403-13.
5. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenetic fibrosing alveo-litis. Am J Respir Crit Care Med. 1994;149:1583-90.
6. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44.
7. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9.
8. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider FR, Varga J. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis. How similar and distinct? Arthritis Rheumatol. 2014;66: 1967-78.
9. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132:214-20.
10. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66:1625-35.
11. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360: 1989-2003.
12. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22:6-19.
13. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): clas-sification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5.
14. Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J. 2011;38:761-9.
15. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154(2 pt 1):400-6.
16. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine con-centrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997;40:743-51.
17. De Santis M, Bosello S, La Torre G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005;6:96.
18. Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993;188:499-506.
19. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005-12.
20. Strange C, Bolster MB, Roth MD, et al; Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in sclero-derma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91-8.
21. Ferri C, Valentini G, Cozzi F, et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139-53.
22. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-6.
23. American Thoracic Society, European Respiratory Society. American Tho-racic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respi-ratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
24. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:121-7.
25. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med. 1998;19:713-31.
26. Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003;124:1215-23.
27. Piper WN, Helwig EB. Progressive systemic sclerosis: visceral manifestations in generalized scleroderma. AMA Arch Derm. 1955;72:535-46.
28. Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134:601-5.
29. Clements PJ, Roth MD, Elashoff R, et al; Scleroderma Lung Study Group. Scleroderma Lung Study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007;66: 1641-7.
30. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977-83.
31. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-54.
32. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multi-center study. Acad Radiol. 2008;15:1004-16.
33. Goldin J, Elashoff R, Kim HJ, et al. Treatment of Scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo. Chest. 2009;136: 1333-40.
34. Frauenfelder T, Winklehner A, Nguyen TD, et al. Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann Rheum Dis. 2014;73:2069-73.
35. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with com-bined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30:2398-405.
36. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54:184-91.
37. Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res. 2012;64:303-10.
38. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189-94.
39. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37:2290-8.
40. Mathai SC, Hammers LK, Champion HC, et al. Survival in pulmonary hyper-tension associated with the scleroderma spectrum of diseases. Arthritis Rheum. 2009;60:569-77.
41. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151-7.
42. Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
43. Hinchcliff M, Fisher A, Schiopu E, Steen VD; PHAROS Investigators. Pul-monary hypertension and recognition of outcomes in scleroderma (PHAROS): Baseline characteristics and description of study population. J Rheumatol. 2011;38:2172-9.
44. Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J. 2009;34:371-9.
45. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum. 2006;36:173-81.
46. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med. 1989;149:589-93.
47. Maddern GJ, Horowitz M, Jamieson GG, Chatterton BE, Collins PJ, Roberts-Thomson P. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology. 1984;87:922-6.
48. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histo-pathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40:241-9.
49. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45:346-54.
50. de Souza RB, Borges CT, Capelozzi VL, et al. Centrilobular fibrosis: an under-recognized pattern in systemic sclerosis. Respiration. 2009;77:389-97.
51. Antoniou KM, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008;20:686-91.
52. Steen V. Predictors of end stage lung disease in systemic sclerosis (editorial). Ann Rheum Dis. 2003;62:97-9.
53. Greenwald R, Tashkin DP, Gong H, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Am J Med. 1987;83:83-92.
54. Wells AU, Latsi P, McCune WJ. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? Am J Respir Crit Care Med. 2007;176:952-3.
55. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146:422-36.
56. Khanna D, Mittoo S, Aggarwal R, et al. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) -Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015;42(11):2168-71.
57. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-70.
58. Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026-34.
59. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal cri-sis. Arthritis Rheum. 1998;41:1613-9.
60. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyi-annopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002;29:298-304.
61. Campos DP, Del Toro ME, Casanovas AP, et al. Are high dose of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Reumatol Clin. 2012;8:58-62.
62. Domiciano DS, Bonfá E, Borges CT, et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol. 2011;30:223-9.
63. Ando K, Motojima S, Doi T, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig. 2013;51:69-75.
64. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2003;29:371-90.
65. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylpredni-solone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002;29:2371-8.
66. Pai BS, Srinivas CR, Sabitha L, Shenoi SD, Balachandran CN, Acharya S. Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol. 1995;34:726-8.
67. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168:1718-9.
68. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O’Callaghan A, Solans-Laqué R, Vilardell-Tarrés M. Effect of mycophenolate sodium in sclero-derma-related interstitial lung disease. Clin Rheumatol. 2011;30:1393-8.
69. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29:1167-8.
70. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tol-erated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30-6.
71. Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in dif-fuse cutaneous systemic sclerosis -a retrospective analysis. Rheumatology. 2007;46:442-5.
72. Tashkin DP, Roth MD, Furst DE, et al. Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (Scleroderma Lung Study (SLS)II): Rationale, design, methods, baseline characteristics/intercorrelations and patients disposition. Am J Respir Crit Care Med. 2013;187:A2921.
73. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-7.
74. Taniguchi H, Ebina M, Kondoh Y, et al; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2009;35:821-9.
75. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfeni-done in patients with idiopathic pulmonary fibrosis (CAPACITY): two random-ized trials. Lancet. 2011;377:1760-9.
76. Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:235-8.
77. Nagai S, Hamada K, Shigematsu M, et al. Open‐label compassionate use one year‐treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002;41:1118-23.
78. Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L. Improved pulmo-nary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India. 2015;32:50-2.
79. Khanna D, Albera C, Fischer A, et al. Safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease -The LOTUSS study. Ann Rheum Dis. 2015;74:S816.
80. Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin -a preliminary report. Clin Rheumatol. 2000;19:207-11.
81. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50:1005-7.
82. Kudo H, Jinnin M, Yamane K, et al. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci. 2013;69:77-80.
83. Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31:S151-6.
84. Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA. Intravenous immunoglobulin may be an effective therapy for refractory active diffuse cutaneous systemic sclerosis. J Rheumatol. 2015;42:236-42.
85. Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24:387-400.
86. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67.
87. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110:1388-96.
88. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. 2011;378:498-506.
89. van Laar JM, Farge D, Sont JK, et al. EBMT/EULAR Scleroderma Study Group transplantation in the treatment of systemic. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490-8.
90. Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet. 2013;381:1116-24.
91. Farge D, Passweg J, van Laar JM, et al; EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63:974-81.
92. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007;34:1636-7.
93. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med. 2005;143:918-20.
94. Denton CP, Engelhart M, Tvede N, et al. An open label pilot study of inf-liximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68:1433-9.
95. Distler JH, Jordan S, Airo P, et al. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol. 2011;29:S40.
96. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from 1-year, proof-of principle study. Rheumatology. 2010;49:271-80.
97. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17-22.
98. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-35.
99. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology. 2008;47:552-3.
100. Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010;40:127-36.
101. Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193-7.
102. Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open label trial. Arthritis Res Ther. 2010;12:R54.
103. Elhai M, Meunier M, Matucci-Cerinic M, et al; EUSTAR (EULAR Sclero-derma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217-20.
104. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93-9.
105. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010;49:2408-12.
106. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214: 199-210.
107. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3:e2696.
108. Sargent J, Milano A, Bhattacharyya S, et al. The TGF-ß responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130:694-705.
109. Denton CP, Merkel PA, Furst DE, et al; Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT−192. Arthritis Rheum. 2007;56: 323-33.
110. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 2008;58:1465-74.
111. Coelho LF, de Oliveira JG, de Oliveira DB, et al. Increased expression of 2’5’oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients. Arch Dermatol Res. 2007;299:259-62.
112. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated inter-feron gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 2006;45:694-702.
113. Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational stimulations to bridge indications for an anti-interferon-a receptor antibody. Clin Pharmacol Ther. 2013;93:483-92.
114. Kuwana M, Medsger TA Jr, Wright TM. Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol. 1997;158:485-91.
115. Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of intersti-tial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009;11:R111.
116. Degiannis D, Seibold JR, Czarnecki M, Rasknova J, Raska K Jr. Soluble inter-leukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum. 1990;33:375-80.
117. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol. 2005;130:568-74.
118. Becker MO, Brückner C, Scherer HU, et al. The monoclonal anti-CD25 anti-body basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis. 2011;70:1340-1.
119. Scherer HU, Burmester GR, Riemekasten G. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis. 2006;65:1245-7.
120. Distler JH, Distler O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford). 2009;48:2-4.
121. Daniels CE, Lasky JA, Limper AH, et al; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604-10.
122. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, Phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003-9.
123. Khanna D, Saggar R, Mayes MD, et al. A one-year, Phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540-6.
124. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63:3547-51.
125. Fraticelli P, Gabrielli B, Pomponio G, et al; Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
126. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-87.
127. Richeldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
128. Shitrit D, Amital A, Peled N, et al. Lung transplantation in patients with sclero-derma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009;23:178-83.
129. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in sclero-derma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54:3954-61.
130. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant. 2000;5:38-43.
131. Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung trans-plantation: a single centre experience. Eur Respir J. 2010;36:893-900.